Indonesia is preparing to support the commercialization of CanSino Biologics’ Ad5-nCoV vaccine candidate as Solution Biologics Sdn Bhd (SOLBIO), a subsidiary of Solution Group Bhd, inked a deal to distribute the Chinese vaccine targeting COVID-19 in Malaysia. Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) is that nation’s drug regulatory. The country follows after the U.S. FDA standards.
Current COVID-19 Situation
Malaysia, with about 32 million people, the extent of COVID-19 infections has been fairly limited to a purported 11,224 present cases and 136 deaths. Of course, the Phase 3 clinical trial there must show the vaccine to be safe and effective, again to U.S. FDA standards.
Should that occur, SOLBIO is ready to pursue the Market Authorization Certificate from the NPRA to commence marketing and distribution of the product known as Ad5-nCoV.
Who is Solutions Group BhD?
Known as a technology investment holding company, Solutions Group Berhad is publicly traded on the Malaysian stock market. The company maintains a number of subsidiaries, including the life sciences-focused SOLBIO mentioned above.
CanSino Biologics in Canada
TrialSite reminds readers that CanSino Biologics and the Chinese government “pulled a fast one” on the entire nation of Canada. The parties on the Canadian side represented by the National Research Council of Canada entered into a contract to co-develop the vaccine via the Canadian Center for Vaccinology at the University of Dalhousie in Nova Scotia. For whatever reason, probably due to escalating political and economic tensions between Canada and China and the United States and China, the Chinese customs never allowed the study vaccine to ship over to Canada. Although a rational approach would be for all countries to come together to fight off the vaccine, that unfortunately hasn’t occurred during this pandemic.